Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease
Version of Record online: 26 DEC 2012
© 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology
Volume 18, Issue 1, pages 117–124, January 2013
How to Cite
ARAI, T., INOUE, Y., TACHIBANA, K., TSUYUGUCHI, K., NISHIYAMA, A., SUGIMOTO, C., SASAKI, Y., KAGAWA, T., MATSUDA, Y. and HAYASHI, S. (2013), Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. Respirology, 18: 117–124. doi: 10.1111/j.1440-1843.2012.02263.x
- Issue online: 26 DEC 2012
- Version of Record online: 26 DEC 2012
- Accepted manuscript online: 17 SEP 2012 04:13AM EST
- Received 16 February 2012; invited to revise 10 April 2012; revised 8 May 2012; accepted 29 May 2012 (Associate Editor: Marcos Restrepo).
Figure S1 Longitudinal observation of the clinical course of patients with high levels of cytomegalovirus (CMV) pp65 antigen (CMV-pp65Ag) (>7.5 cells per 5 × 104 peripheral blood leucocytes) at the initial CMV detection. Of all the CMV-pp65Ag-positive cases, 25 patients showed high levels of CMV-pp65Ag. The CMV-pp65Ag became negative in 12 out of the 22 patients treated with ganciclovir (GCV). However, three out of the 12 patients died within one month. Three out if the four patients, whose CMV-pp65Ag levels remained high in spite of GCV therapy, died within one month. Four patients died within one month after the start of GCV therapy before reevaluation of CMV-pp65Ag. Three patients died before the diagnosis of CMV infection and before GCV therapy could be initiated.
Table S1 Underlying DPLDs and CMV-pp65Ag evaluation
Table S2 Onset of underlying DPLDs
Table S3 Patient Details of CMV-pp65Ag detected and non-detected cases
Table S4 Clinical parameters at the start of immunosuppressive treatment and the interval leading to the onset of CMV infection (univariate analysis)*
Table S5 Clinical parameters at the onset of CMV infection and survival from the CMV infection (univariate analysis)*
|resp2263_sm_FigS1.tif||7048K||Supporting info item|
|resp2263_sm_TS1-S5.doc||141K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.